IJE Advance Access originally published online on January 27, 2007
International Journal of Epidemiology 2007 36(1):29-31; doi:10.1093/ije/dyl305
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Published by Oxford University Press on behalf of the International Epidemiological Association © The Author 2007; all rights reserved.
Cochrane Column
South African Cochrane Centre, Medical Research Council, PO Box 19070, Tygerberg 7505, South Africa. Email: taryn.young@mrc.ac.za
| The first 150 words of the full text of this article appear below. |
This month we feature the Cochrane Review assessing the effects of screening in reducing prostate-specific and all-cause mortality.
The aim of the Column is to highlight Cochrane Reviews of relevance to public health, and to stimulate debate on relevance, feasibility and acceptability. The Cochrane Collaboration (http://www.cochrane.org) is an international, non-profit organization that prepares and disseminates up-to-date systematic reviews on the effects of healthcare interventions in order to help people make well-informed decisions. Systematic reviews aim to answer focused healthcare questions by systematically identifying and evaluating all relevant research studies and synthesizing their results.
If you are interested in contributing to the Cochrane Column or The Cochrane Collaboration, contact me at the South African Cochrane Centre.
Screening for prostate cancer
1 Monash Institute of Health Services Research, Monash University, Clayton VIC 3168 Australia.
2 Minneapolis VA Center for Chronic Disease Outcomes Research, Minneapolis, MN 55417, USA.
Prostate cancer is a common cause of cancer in men worldwide. There is debate around the effectiveness of screening methods for prostate canceraround the digital rectal examination (DRE) and prostate specific antigen (PSA)
Department of Social Medicine, University of Bristol, UK.
Department of Urology, University of Stellenbosch and Tygerberg Hospital, Cape Town, South Africa.